PD-L1 Antibody (YA4539)(PBS only)

Cat. No.: HY-P84842A: Data Sheet User Guide for Antibodies
FAQs
Technical Support

PD-L1 Antibody (YA4539) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to PD-L1.

For research use only. We do not sell to patients.

Size		Stock
50 μL		Get quote
100 μL		Get quote

* Please select Quantity before adding items.

WB: Western Blot;
IHC-P: Immunohistochemistry-Paraffin;
IHC-F: Immunohistochemistry-Frozen;
ICC/IF: Immunocytochemistry/Immunofluorescence;
IF-Tissue: Immunofluorescence-Tissue;
mIHC: Multiplex Immunohistochemical;
IP: Immunoprecipitation;
ChIP: Chromatin Immunoprecipitation;
FC: Flow Cytometry;
ELISA: Enzyme Linked Immunosorbent Assay

Product Detail
Background
Documentation

Description

PD-L1 Antibody (YA4539) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to PD-L1.

Host

Mouse

Molecular Weight

Predicted band size: 33 kDa;

Observed band size: 46 kDa

Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.

Species Reactivity

Human

SwissProt ID

Q9NZQ7

Gene ID

29126 [NCBI]

Immunogen

Purified recombinant fragment of human CD274 (AA: 24-153) expressed in E. Coli.

Application &
Dilution Ratio

Application	Dilution Ratio
IHC-P IHC-P: Immunohistochemistry-Paraffin	1:200-1:1000
FC FC: Flow Cytometry	1:200-1:400
ELISA ELISA: Enzyme Linked Immunosorbent Assay	1:10000

Purity	affinity purified.	Conjugation	Non-conjugated
Isotype	IgG2b

Appearance

Liquid

Formulation

Supplied in PBS, pH 7.4.

Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

Shipping

Shipping with blue ice.

Background

Function：Plays a critical role in induction and maintenance of immune tolerance to self (PubMed:11015443, PubMed:28813410, PubMed:28813417, PubMed:31399419). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443, PubMed:28813410, PubMed:28813417, PubMed:36727298). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077). Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis (PubMed:32929201); The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed:28813410, PubMed:28813417). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity)

Subcellular Localization：Cell membrane; Single-pass type I membrane protein; Early endosome membrane; Single-pass type I membrane protein; Recycling endosome membrane; Single-pass type I membrane protein; Nucleus; Cell membrane; Single-pass type I membrane protein; Endomembrane system; Single-pass type I membrane protein; Secreted

Expression：
Tissue_specificity:It is highly expressed in the heart, skeletal muscle, placenta, and lungs. It is weakly expressed in the thymus, spleen, kidneys, and liver. It is expressed on activated T cells and B cells, dendritic cells, keratinocytes, and monocytes; it is widely expressed, with the highest expression in the lungs, liver, pituitary gland, and various peripheral blood cells (including neutrophils and certain subtypes of lymphocytes and myeloid cells) .

Induction:Up-regulated on T- and B-cells, dendritic cells, keratinocytes and monocytes after LPS and IFNG activation. Up-regulated in B-cells activated by surface Ig cross-linking

Isoforms & Post-Translational Modification：Q9NZQ7 has 4 isomers: Q9NZQ7-1: 33275 Da (predicted); Q9NZQ7-2: 20246 Da (predicted); Q9NZQ7-3: 20454 Da (predicted); Q9NZQ7-4: 28050 Da (predicted).
Ubiquitinated; STUB1 likely mediates polyubiquitination of PD-L1/CD274 triggering its degradation (PubMed:28813410). Ubiquitinated by MARCHF8; leading to degradation (PubMed:34183449). Deubiquitinated by USP22; leading to stabilization (PubMed:31399419)

Subunit：Interacts with PDCD1 (PubMed:11015443, PubMed:18287011, PubMed:26602187). Interacts (via transmembrane domain) with CMTM4 and CMTM6 (PubMed:28813410, PubMed:28813417). Interacts with (phosphorylated) STAT3; promoting nuclear translocation (PubMed:32929201). Interacts with CD80 (PubMed:36727298)

Synonyms

B7-H; B7H1; PDL1; PD-L1; PDCD1L1; PDCD1LG1,CD274

Documentation

User Guide for Antibodies (1077 KB)